Evidence map›Paper›PMID 34657975›Full record

ArticleNeurosurgical review2022

Development and assessment of machine learning models for predicting recurrence risk after endovascular treatment in patients with intracranial aneurysms.

ShiTeng Lin, Yang Zou, Jue Hu, Lan Xiang, LeHeng Guo, XinPing Lin, DaiZun Zou, Xiaoping Gao, Hui Liang, JianJun Zou and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neurosurgical review, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Systematic Review of Radiomics and Artificial Intelligence in Intracranial Aneurysm Management.Journal of neuroimaging : official journal of the American Society of Neuroimaging
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

ShiTeng LinSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
Yang ZouSchool of Pharmacy, University of Sydney, Sydney, Australia.
Jue HuDepartment of Neurology, Changsha Central Hospital, Changsha, China.
Lan XiangDepartment of Neurology, The First Affiliated Hospital (People's Hospital of Hunan Province), Hunan Normal University, Changsha, China.
LeHeng GuoDepartment of Neurology, The First Affiliated Hospital (People's Hospital of Hunan Province), Hunan Normal University, Changsha, China.
XinPing LinSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
DaiZun ZouSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
Xiaoping GaoDepartment of Neurology, The First Affiliated Hospital (People's Hospital of Hunan Province), Hunan Normal University, Changsha, China.
Hui LiangDepartment of Neurology, The First Affiliated Hospital (People's Hospital of Hunan Province), Hunan Normal University, Changsha, China.
JianJun ZouDepartment of Clinical Pharmacology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. zoujianjun100@126.com.
ZhiHong ZhaoDepartment of Neurology, Changsha Central Hospital, Changsha, China. zhaozhihong51818@hotmail.com.
XiaoMing DaiDepartment of Hepatobiliary and Pancreas Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China. 357442391@qq.com.ORCID http://orcid.org/0000-0003-0886-3153
China Pharmaceutical University · CNHunan Normal University · CNChangsha Central Hospital · CNFirst Affiliated Hospital of University of South China · CNThe University of Sydney · AU

Funding

Hunan innovation guidance grant of clinical medical technology 2020SK50920Jiangsu Provincial Key Research and Development Program BE2017613National Natural Science Foundation of China 81673511Six Talent Peaks Project in Jiangsu Province WSN-151
6 · The paper itself

Abstract

Intracranial aneurysms (IAs) remain a major public health concern and endovascular treatment (EVT) has become a major tool for managing IAs. However, the recurrence rate of IAs after EVT is relatively high, which may lead to the risk for aneurysm re-rupture and re-bleed. Thus, we aimed to develop and assess prediction models based on machine learning (ML) algorithms to predict recurrence risk among patients with IAs after EVT in 6 months. Patient population included patients with IAs after EVT between January 2016 and August 2019 in Hunan Provincial People's Hospital, and an adaptive synthetic (ADASYN) sampling approach was applied for the entire imbalanced dataset. We developed five ML models and assessed the models. In addition, we used SHapley Additive exPlanations (SHAP) and local interpretable model-agnostic explanation (LIME) algorithms to determine the importance of the selected features and interpret the ML models. A total of 425 IAs were enrolled into this study, and 66 (15.5%) of which recurred in 6 months. Among the five ML models, gradient boosting decision tree (GBDT) model performed best. The area under curve (AUC) of the GBDT model on the testing set was 0.842 (sensitivity: 81.2%; specificity: 70.4%). Our study firstly demonstrated that ML-based models can serve as a reliable tool for predicting recurrence risk in patients with IAs after EVT in 6 months, and the GBDT model showed the optimal prediction performance.

Indexed as

Aneurysm, RupturedIntracranial AneurysmAlgorithmsArea Under CurveHumansMachine LearningEndovascular treatmentIntracranial aneurysmsMachine learningRecurrence

Identifiers

PMID34657975
OpenAlexW3167582001

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.